FDA Expands Indication of Dust Mite Allergy Drug to Include Young Children
By Lori Solomon HealthDay Reporter
WEDNESDAY, March 5, 2025 -- The U.S. Food and Drug Administration has expanded its indication of Odactra, a house dust mite allergen tablet, for the treatment of house dust mite-induced allergic rhinitis, with or without conjunctivitis, to include children ages 5 through 11 years.
Odactra is an allergy immunotherapy and is administered sublingually as a small tablet that dissolves under the tongue.
The approval was based on data from a phase 3 clinical trial that included 1,460 children ages 5 to 11 years old with persistent allergic rhinitis symptoms for a year, despite receiving symptom-relieving medication. Children randomly assigned to Odactra experienced a relative reduction in total combined rhinitis score of 22 percent versus placebo. Four patients receiving Odactra experienced severe treatment-related adverse events, including oral and ear itchiness, burning or tingling sensation in the mouth, lip swelling, and abdominal pain. However, no participants reported treatment-related anaphylaxis or adverse events requiring treatment with epinephrine.
"The pediatric indication for Odactra is significant because it provides physicians and parents a new option for treating these younger patients," Jackie Eghrari-Sabet, M.D., an allergist and immunologist at George Washington University in Washington, D.C., said in a statement. "In addition to the convenience of sublingual administration, Odactra has been shown to reduce their allergy symptoms and reliance on symptomatic medications."
Expanded approval of Odactra was granted to ALK.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted March 2025
Read this next
Fatal Snakebite at Tennessee Park Highlights Risks in the Wild
FRIDAY, Aug. 22, 2025 — Authorities in Tennessee reported a rare and tragic death after a hiker was bitten by a rattlesnake. Fatal snakebites are extremely uncommon in the...
COVID-19 Linked To Asthma, Seasonal Allergies
FRIDAY, Aug. 22, 2025 — COVID-19 infection might increase a person’s risk of developing asthma, seasonal allergies and long-lasting sinus problems, a new study...
Why Do Some Kids Benefit More From Exposure Therapy To Food Allergens?
FRIDAY, Aug. 15, 2025 — Some kids are helped by exposure therapy to food allergens like peanuts, with their allergies gradually diminishing as they eat small amounts of...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.